Application of sentinel lymph node biopsy in patients with melanoma.
|Abstract||The findings suggest that immunohistochemistry could effectively improve the detection of positive SLN in melanoma. Cases with SLN metastatic deposits ≤2 mm are less likely to have further metastases in NSLN. There is a need for prospective large-population based studies to identify a subgroup of SLN positive patients who can safely be spared complete lymph node dissection.|
Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection.
|Journal Title||zhonghua bing li xue za zhi = chinese journal of pathology|
|Publication Year Start||2018-01-01|
PMID- 29783803 OWN - NLM STAT- MEDLINE DCOM- 20180611 LR - 20180611 IS - 0529-5807 (Print) IS - 0529-5807 (Linking) VI - 47 IP - 5 DP - 2018 May 8 TI - [Application of sentinel lymph node biopsy in patients with melanoma]. PG - 360-365 LID - 10.3760/cma.j.issn.0529-5807.2018.05.009 [doi] AB - Objective: To investigate the difference between routine hematoxylin-eosin (HE) staining and immunohistochemistry in diagnosing metastatic melanoma in sentinel lymph node (SLN) metastases, and to evaluate the association of SLN tumor burden with the status of non-sentinel lymph nodes (NSLN). Methods: 126 melanoma patients were treated with SLN biopsy and further examined with immunohistochemistry at Fudan University Shanghai Cancer Center between 2010 and 2016, and the status of SLN was respectively estimated by HE stain and immunohistochemistry (S-100 protein, HMB45, Melan A and SOX10). In 39 patients who were treated with complete lymph node dissection, characteristics of SLN tumor burden (maximum diameter of the tumor deposit, tumor penetrative depth and the microanatomic location of the metastasis) and the associations of SLN tumor burden with the involvement of NSLN were all evaluated. Results: Of the total 126 cases, 33 (26.2%) were positive by HE staining and 49 (38.3%) were positive by immunohistochemistry. S-100 protein was positive in 48 out of 49 cases (98.0%). HMB45 was positive in 46 out of 49 cases (93.9%). Melan A was positive in 47 out of 49 cases (96.0%). SOX10 was positive in 8 out of 8 cases. The outcome indicated that the application of immunohistochemistry identified positive SLN missed by HE stain in about 12.1% of cases. Of the 39 patients who were treated with complete lymph node dissection, six showed metastases in NSLN. The frequency of metastases in NSLN was 15.4% (6/39) when SLN was positive. Additionally, the frequency of metastases in NSLN in cases with SLN metastatic deposits </=2 mm was significantly lower than that in cases with SLN metastatic deposits >2 mm; eight cases with SLN metastatic deposits <0.2 mm had no additional positive NSLN. Conclusions: The findings suggest that immunohistochemistry could effectively improve the detection of positive SLN in melanoma. Cases with SLN metastatic deposits </=2 mm are less likely to have further metastases in NSLN. There is a need for prospective large-population based studies to identify a subgroup of SLN positive patients who can safely be spared complete lymph node dissection. FAU - Ren, M AU - Ren M AD - Department of Pathology, Shanghai Cancer Center, Fudan University and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Kong, Y Y AU - Kong YY FAU - Cai, X AU - Cai X FAU - Shen, X X AU - Shen XX FAU - Lyu, J J AU - Lyu JJ LA - chi PT - Journal Article PL - China TA - Zhonghua Bing Li Xue Za Zhi JT - Zhonghua bing li xue za zhi = Chinese journal of pathology JID - 0005331 RN - 0 (Coloring Agents) RN - 0 (MART-1 Antigen) RN - 0 (Neoplasm Proteins) RN - 0 (S100 Proteins) RN - 0 (SOXE Transcription Factors) RN - TDQ283MPCW (Eosine Yellowish-(YS)) RN - YKM8PY2Z55 (Hematoxylin) SB - IM MH - China MH - Coloring Agents MH - Eosine Yellowish-(YS) MH - Hematoxylin MH - Humans MH - Immunohistochemistry MH - Lymph Node Excision MH - Lymphatic Metastasis MH - MART-1 Antigen/analysis MH - Melanoma/chemistry/*pathology MH - Neoplasm Proteins/analysis MH - Prospective Studies MH - S100 Proteins/analysis MH - SOXE Transcription Factors/analysis MH - *Sentinel Lymph Node Biopsy MH - Skin Neoplasms/chemistry/*pathology MH - Tumor Burden OTO - NOTNLM OT - Immunohistochemistry OT - Malignant melanoma OT - Sentinel lymph node OT - Tumor burden EDAT- 2018/05/23 06:00 MHDA- 2018/06/12 06:00 CRDT- 2018/05/23 06:00 PHST- 2018/05/23 06:00 [entrez] PHST- 2018/05/23 06:00 [pubmed] PHST- 2018/06/12 06:00 [medline] PST - ppublish SO - Zhonghua Bing Li Xue Za Zhi. 2018 May 8;47(5):360-365.